(Date:1/7/2009)... Applauds Legislation Aimed at Protecting Medicare...h Congress , , ALEXANDRIA, Va., Jan. 7 Physi...uld no longer be limited by arbitrary financial ca...ate and House of Representatives, according to the... , The Medicare Access to Rehabilitation Services ...
(Date:1/7/2009)...llowing is a statement by Lois Aronstein, AARP NY ...e of the State address put forth recommendations o...lth care and financial security of New Yorkers of ...osing to expand the Family Health Plus Program to ...ore than 400,000 additional New Yorkers eligible f...
(Date:1/7/2009)...ied mutations in a gene that predict a high likeli...ic leukemia (ALL). Although the researchers cautio... changes in the gene, called IKZF1 or IKAROS, lead...rovide the basis for future diagnostic tests to as...lecular test to identify this genetic marker in AL...
(Date:1/7/2009)...n. 7 Stryker Corporation,(NYSE: SYK ) announced...nvestor,conference: , , January 14, 200...al J.P. Morgan Healthcare Conference, S...cast of the Company,s presentation will be availab...he For Investors page. The,presentation for the J...
Breaking Medicine News(10 mins):Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 2Health News:Senate and House Introduce Legislation to Repeal Therapy Caps 3Health News:Gene abnormality found to predict childhood leukemia relapse 2Health News:Gene abnormality found to predict childhood leukemia relapse 3Health News:Gene abnormality found to predict childhood leukemia relapse 4Health News:Stryker To Present at Investor Conference 2(Date:1/6/2009)...LLE, Md., Jan. 6 Sequel...ny focused on diseases of epidemic potential, anno...r the treatment of tuberculosis (TB), was the firs...clinical program contract to Dynport Vaccine Compa...awarded by the National Institute of Allergy and I...
(Date:1/6/2009)...RIS, France, January 6 ,... the Collaboration Until,December 2011 , -...clude Antibody,Discovery in Ophthalmology , ...it if Allergan,Sublicenses to a Third Party ,,...y announced a reinforcement,of its existing drug ...
(Date:1/5/2009)...N JOSE, Calif., Jan. 5 Women under...terone medication to help support early,pregnancy...of this medication,can be painful for patients. ... be administered by subcutaneous injection or vagi...tter patient tolerance. , With patient well...
(Date:12/29/2008)...DA, Md., Dec. 29 The wi...earch Protection was announced today by Dr. Peter ...h Improvement Institute. , , The winner of the... Anderson Cancer Center -- for its best practice...rogram provides for 1) enhanced human subjects pro...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 22008 Human Research Protection Award Recipients Announced 2Arius announces new findings in Trop 2 and CD59 CANCER antibody programs 1510 1Arius announces new findings in Trop 2 and CD59 CANCER antibody programs 1510 2Arius announces new findings in Trop 2 and CD59 CANCER antibody programs 1510 3Potential Early Warning System for Lung Cancer Identified 661 1Potential Early Warning System for Lung Cancer Identified 661 2Potential Early Warning System for Lung Cancer Identified 661 3Imaging shows structural changes in mild traumatic brain injury 4611 1Imaging shows structural changes in mild traumatic brain injury 4611 2Imaging shows structural changes in mild traumatic brain injury 4611 3U of I scientist does nutritional detective work in Botswana 971 1U of I scientist does nutritional detective work in Botswana 971 2U of I scientist does nutritional detective work in Botswana 971 3..., 2007-Pozen Inc. (NASDAQ: POZN),today announced ...of-of-concept study conducted during the fourth qu... 325mg of aspirin surrounded by,a 20mg coating of ...inhibitor. , The PA 325, 28 day study, involved tw...ubject was treated with either once a day,commerci...
... HILL, N.C., US, March 06, 2007,/PRNewswire/ -- AO...tibio, Inc. ("Lantibio") today announced positive ...e-blinded Phase II clinical,study of Moli1901, an ...F"). Moli1901 is being developed by AOP Orphan in,...eement with,Lantibio. The study, performed at mult...
Other Medicine Technology:Pozen Announces Positive Outcome for PA 325 2Pozen Announces Positive Outcome for PA 325 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 2AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 3AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II,Study with Novel Cystic Fibrosis Therapy 4...the first,diagnostic hepatitis assay approved by t...ing run in a random access format on,the VITROS EC...w you,can run a hepatitis test at any time, in,any...the qualitative in vitro determination of total,an...
This SIGNET anti-PSA antibody gives positive staining of prostatic epithelium in all cases of benign hyperplasia. In cases of prostatic cancer, 65% give intense staining and 34% give definite but wea
...uential binding of HCG from patient samples to two... immobilized on microtiter well plates, and other ...e enzyme horseradish peroxidase. After a washing s...eloped. The enzymatic reaction (color) is directly...
For the quantitative determination of Glycohemoglobin in blood.
Medicine Products: